You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

OBETICHOLIC ACID Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Obeticholic Acid patents expire, and what generic alternatives are available?

Obeticholic Acid is a drug marketed by Apotex, Lupin Ltd, and MSN. and is included in three NDAs.

The generic ingredient in OBETICHOLIC ACID is obeticholic acid. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the obeticholic acid profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OBETICHOLIC ACID?
  • What are the global sales for OBETICHOLIC ACID?
  • What is Average Wholesale Price for OBETICHOLIC ACID?
Drug patent expirations by year for OBETICHOLIC ACID
Recent Clinical Trials for OBETICHOLIC ACID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Intercept PharmaceuticalsPhase 2/Phase 3
Universitaire Ziekenhuizen KU LeuvenN/A
Intercept PharmaceuticalsN/A

See all OBETICHOLIC ACID clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for OBETICHOLIC ACID
Paragraph IV (Patent) Challenges for OBETICHOLIC ACID
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
OCALIVA Tablets obeticholic acid 5 mg and 10 mg 207999 5 2020-05-27

US Patents and Regulatory Information for OBETICHOLIC ACID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex OBETICHOLIC ACID obeticholic acid TABLET;ORAL 214862-001 May 30, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Ltd OBETICHOLIC ACID obeticholic acid TABLET;ORAL 214980-002 May 30, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Apotex OBETICHOLIC ACID obeticholic acid TABLET;ORAL 214862-002 May 30, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin Ltd OBETICHOLIC ACID obeticholic acid TABLET;ORAL 214980-001 May 30, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for OBETICHOLIC ACID

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
ADVANZ PHARMA Limited Ocaliva obeticholic acid EMEA/H/C/004093
Ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.
Authorised no no yes 2016-12-12
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.